为进一步完善北京佰仁医疗科技股份有限公司（以下简称"公司"）法人治理结 构，促进公司规范运作，充分发挥独立董事在公司治理中的作用，维护公司整体利 益，保障全体股东特别是中小股东的合法权益不受损害，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》《上市公司独立董事管 理办法》《上市公司治理准则》等法律法规、规章制度、规范性文件以及《北京佰仁 医疗科技股份有限公司章程》（以下简称"《公司章程》"）的相关规定，特制定本制 度。 第一章 总则 第一条 本制度所指的独立董事，是指不在公司担任除董事外的其他职务，并 与公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影 响其进行独立客观判断关系的董事。 北京佰仁医疗科技股份有限公司 独立董事工作制度 2025 年 8 月 北京佰仁医疗科技股份有限公司 独立董事工作制度 第二条 独立董事对公司及全体股东负有诚信与勤勉义务。独立董事应当按照 法律、行政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、证券 交易所业务规则和《公司章程》的规定，认真履行职责，在董事会中发挥参与决策、 监督制衡、专业咨询作用，维护公司 ...

北京佰仁医疗科技股份有限公司 信息披露管理制度 2025 年 8 月 北京佰仁医疗科技股份有限公司 信息披露管理制度 第一章 总则 第一条 为提高北京佰仁医疗科技股份有限公司（以下简称"公司"）的信息 披露质量，规范公司的信息披露行为，保护投资者的合法权益，根据《中华人民 共和国公司法》、《中华人民共和国证券法》、《上海证券交易所科创板股票上 市规则》（以下简称"《科创板上市规则》"）、中国证券监督管理委员会（以下 简称"中国证监会"）发布的《上市公司信息披露管理办法》、《科创板上市公司 持续监管办法（试行）》等法律、法规、规范性文件以及《北京佰仁医疗科技股 份有限公司章程》（以下简称"公司章程"）等相关制度规定，结合公司实际情况， 制定本制度。 第二条 本制度所称"信息披露"是指公司将对公司股票及其衍生品种交易价 格可能产生较大影响而投资者尚未得知的信息，在规定的期限内，通过指定的媒 体，以规定的方式向社会公众公布，并按照规定报送证券监管部门。 第二章 信息披露的基本原则和一般规定 第一节 基本原则 第三条 信息披露义务人应当真实、准确、完整、及时地披露信息，不得有 虚假记载、误导性陈述或者重大遗漏。 公司 ...

北京佰仁医疗科技股份有限公司 章 程 2025 年 8 月 | 第一章 | 总则…………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 3 | | --- | --- | | 第二章 | 经营宗旨和范围 . | | 第三章 | 放分 | | 第一节 | 股份发行 . | | 第二节 | 股份增减和回购 | | 第三节 | 股份转让 . | | | 第四章 股东和股东会 . | | 第一节 | 股东 . | | 第二节 | 控股股东和实际控制人 . | | 第三节 | 股东会的一般规定 . | | 第四节 | 股东会的召集 | | 第五节 | 股东会的提案与通知 . | | 第六节 | 股东会的召开 | | 第七节 | 股东会的表决和决议 | | | 第五章 董事和董事会 . | | 第一节 | 董事 . | | 第二节 | 董事会 | | 第三节 | 独立董事 | | | 第四节 董事会专门委员会 . | | 第六章 | 总经理 ...

北京佰仁医疗科技股份有限公司 累积投票制实施细则 2025 年 8 月 北京佰仁医疗科技股份有限公司 累积投票制实施细则 第一条 为维护中小股东的利益，完善北京佰仁医疗科技股份有限公司（以 下简称"公司"）法人治理结构，规范公司选举董事行为，根据中国证监会《上市 公司治理规则》、《北京佰仁医疗科技股份有限公司章程》（以下简称"《公司 章程》"）及其他有关规定，特制定本实施细则。 第二条 本实施细则所指的累积投票制是指公司股东会在选举两名以上的 董事时采用的一种投票方式。即公司股东会选举董事时，股东所持的每一有效表 决权股份拥有与该次股东会应选董事总人数相等的投票权，股东拥有的投票权等 于该股东持有股份数与应选董事总人数的乘积。股东既可以用所有的投票权集中 投票选举一位候选董事，也可以将投票权分散行使、投票给数位候选董事。得票 数超过出席股东会股东所持有效表决权股份（以未累积的股份数为准）的二分之 一为候选人当选的前提条件，公司按得票多少依次确定最终应选人数范围内的当 选董事。 第三条 股东会选举产生的董事人数及结构应符合《公司章程》的规定。 第四条 本实施细则所称"董事"包括独立董事和非独立董事。由职工代表担 ...

Core Points - The Sci-Tech Innovation 50 Index experienced a slight increase, closing at 1149.15 points with a gain of 0.09% and a trading volume of approximately 657.2 billion [1] - Most stocks on the Sci-Tech board declined, with 165 stocks rising; high-priced stocks showed mixed performance while low-priced stocks mostly fell [1] - In specific sectors, stocks related to environmental protection, healthcare, and biopharmaceuticals were active, whereas semiconductor, communication equipment, and electrical equipment stocks declined [1] Trading Performance - On August 21, the average decline for 589 stocks on the Sci-Tech board was 0.93%, with an average turnover rate of 3.82% and a total trading volume of 217.6 billion [1] - The average volatility for the stocks was 4.64% [1] Individual Stock Performance - Sanwei Xinan led the gainers with a 20% increase, while Dongxin Co. had the largest decline at 12.37% [2] - Cambrian's trading volume was the highest at 11.93 billion, while ST Pava had the lowest at 1.439 million [3] Turnover Rate - Yingshi Innovation had the highest turnover rate at 23.30%, while Bairen Medical had the lowest at 0.28% [4]

Core Viewpoint - The company Baijun Medical has a high rolling price-to-earnings (PE) ratio of 98.10, significantly above the industry average of 59.49, indicating potential overvaluation in the medical device sector [1][2] Company Summary - Baijun Medical's closing stock price on August 19 was 121.43 yuan, down 1.54%, with a total market capitalization of 16.727 billion yuan [1] - The company specializes in the research, production, sales, and service of medical devices, with key products including various types of biological patches and heart valve systems [1] - As of March 31, 2025, the number of shareholders increased to 3,099, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows revenue of 100 million yuan, a year-on-year increase of 31.30%, and a net profit of 32.5043 million yuan, up 290.69%, with a gross profit margin of 85.72% [1] Industry Summary - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, positioning Baijun Medical at 104th in the industry ranking [2] - Other companies in the industry have significantly lower PE ratios, with the lowest being 11.65 for Jiuan Medical and the highest being 20.67 for Antu Biology [2]

Core Viewpoint - Beijing Bairen Medical Technology Co., Ltd. has had its application for the registration of a patent foramen ovale (PFO) occluder accepted by the National Medical Products Administration, indicating a significant step in the development of this medical device [1][3]. Group 1: Product Information - The PFO occluder is a self-expanding, mushroom-shaped implant made from nickel-titanium alloy wire, designed to close the abnormal shunt caused by a patent foramen ovale [3]. - The device is intended to prevent complications associated with PFO, such as unexplained strokes and migraines, by effectively blocking the passage between the heart's atria [2][3]. - Clinical studies have shown that the PFO occluder can significantly reduce or eliminate migraine attacks, highlighting its therapeutic potential [2]. Group 2: Market Potential - The incidence of PFO in the general population ranges from 22% to 38%, with rates as high as 32% to 50% in patients with unexplained ischemic strokes, indicating a substantial patient base for the PFO occluder [2]. - The market for PFO occluders is expected to continue growing, with the number of implants increasing from 21,000 in 2021 to an estimated 54,000 by 2024, reflecting a strong demand for this treatment option [2]. Group 3: Regulatory Status - The acceptance of the registration application for the PFO occluder does not guarantee approval, and the company acknowledges the uncertainty regarding the impact of this product on its future performance [3].

Core Viewpoint - The announcement indicates that the registration application for the patent foramen ovale (PFO) occluder developed by the company has been officially accepted by the National Medical Products Administration [2] Company Summary - The company, Baijun Medical, has recently made progress in its product development by having its PFO occluder registration application accepted [2]

Core Viewpoint - Beijing Bairen Medical Technology Co., Ltd. has announced that its application for the registration of a patent foramen ovale (PFO) occluder has been officially accepted by the National Medical Products Administration, indicating progress in the development of this medical device [1]. Group 1: Product Information - The application pertains to a Class III medical device, specifically a PFO occluder, with acceptance number CQZ2501513 [1]. - PFO is a physiological channel left over from embryonic heart septum development, which can lead to various health issues, including unexplained strokes and migraines [1][2]. - The PFO occluder is designed as a self-expanding mushroom-shaped implant made from nickel-titanium alloy wire, lined with a PET polyester membrane, which effectively closes the abnormal shunt [3]. Group 2: Market Potential - The incidence of PFO in the general population ranges from 22% to 38%, and it is found in 32% to 50% of patients with unexplained ischemic strokes [2]. - The market for PFO occluders is expected to continue growing, with increasing recognition of their effectiveness in preventing strokes and reducing migraine symptoms [2][3]. - The product's safety and efficacy have been confirmed through preclinical studies and clinical trials, meeting clinical usage requirements [3].

受理号：CQZ2501513 证券代码：688198 证券简称：佰仁医疗 公告编号：2025-026 北京佰仁医疗科技股份有限公司 关于自愿披露卵圆孔未闭封堵器注册申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，北京佰仁医疗科技股份有限公司（以下简称"公司"）研发的卵圆孔未 闭封堵器注册申请获国家药品监督管理局正式受理，受理信息如下： 申请事项：境内III类医疗器械注册申请 项目名称：卵圆孔未闭封堵器 卵圆孔是心脏房间隔胚胎时期遗留下来的一个生理性通道，大多数人出生后 5~7个月左右融合形成永久性房间隔，若未融合则卵圆窝中间遗留一个永久性的裂缝 样异常通道，即卵圆孔未闭（patent foramentovale，PFO）。PFO可能作为血栓、空 气、脂肪、血管活性物质从静脉系统进入动脉系统的通道，可导致不明原因脑卒中、 短暂性缺血发作、偏头痛、减压病、体位相关性低氧血症等症状，属于结构性心脏 病。 一般人群中PFO的发生率为 22%~38%，而在原因不明的缺血性脑梗死中患PFO 者高达32%~50 ...